

MASSACHUSETTS MEDICAL SOCIETY LICENSE TERMS AND CONDITIONS

Aug 21, 2019

This Agreement between Lorenza Rimassa ("You") and Massachusetts Medical Society ("Massachusetts Medical Society") consists of your license details and the terms and conditions provided by Massachusetts Medical Society and Copyright Clearance Center.

License Number	4653550222511
License date	Aug 21, 2019
Licensed Content Publisher	Massachusetts Medical Society
Licensed Content Publication	The New England Journal of Medicine
Licensed Content Title	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Licensed Content Date	Jul 5, 2018
Licensed Content Volume	379
Licensed Content Issue	1
Type of Use	Journal/Magazine
Requestor type	NEJM author of original work
Portion	figure/table
Number of figures/tables	2
Include high res file(s) delivery	no
Format	electronic
Will you be translating?	no
Circulation	10000
Distributing to	Worldwide
Title of new article	Targeted agents for second-line treatment of advanced hepatocellular carcinoma
Lead author	Lorenza Rimassa
Title of targeted journal	World Journal of Gastrointestinal Oncology
Publisher	wjgnet
Expected publication date	Sep 2019
Portions	Table 2, Table S4
Requestor Location	Lorenza Rimassa Via Savona 3A Milan, Milan 20144 Italy Attn: Lorenza Rimassa
Total	0.00 EUR
Terms and Conditions	

Introduction

The publisher for this copyrighted content is Massachusetts Medical Society ("MMS"). By clicking "accept" in connection with completing this licensing transaction, you agree that the

ELSEVIER LICENSE TERMS AND CONDITIONS

Aug 21, 2019

This Agreement between Lorenza Rimassa ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.

License Number	4653551055332
License date	Aug 21, 2019
Licensed Content Publisher	Elsevier
Licensed Content Publication	The Lancet
Licensed Content Title	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Licensed Content Author	Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder, René Gerolami, Gianluca Masi, Paul J Ross, Tianqiang Song, Jean-Pierre Bronowicki et al.
Licensed Content Date	7-13 January 2017
Licensed Content Volume	389
Licensed Content Issue	10064
Licensed Content Pages	11
Start Page	56
End Page	66
Type of Use	reuse in a journal/magazine
Requestor type	academic/educational institute
Intended publisher of new work	Other
Portion	figures/tables/illustrations
Number of figures/tables/illustrations	2
Format	electronic
Are you the author of this Elsevier article?	No
Will you be translating?	No
Original figure numbers	Table 2, Table 3
Title of the article	Targeted agents for second-line treatment of advanced hepatocellular carcinoma
Publication new article is in	World Journal of Gastrointestinal Oncology
Publisher of the new article	wjgnet
Author of new article	Lorenza Rimassa
Expected publication date	Sep 2019

Estimated size of new article 1
(number of pages)

Requestor Location

Lorenza Rimassa
Via Savona 3A

Milan, Milan 20144
Italy
Attn: Lorenza Rimassa

Publisher Tax ID

GB 494 6272 12

Billing Type

Credit Card

Credit card info

American Express ending in 3003

Credit card expiration

07/2023

Price

124.31 EUR

Tax/VAT (20%)

24.86 EUR

Total

149.17 EUR

Terms and Conditions

INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at permissions@elsevier.com). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

**ELSEVIER LICENSE
TERMS AND CONDITIONS**

Aug 21, 2019

This Agreement between Lorenza Rimassa ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.

License Number	4653560550694
License date	Aug 21, 2019
Licensed Content Publisher	Elsevier
Licensed Content Publication	The Lancet Oncology
Licensed Content Title	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Licensed Content Author	Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard S Finn, Peter R Galle, Josep M Llovet, Eric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun-Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg et al.
Licensed Content Date	Feb 1, 2019
Licensed Content Volume	20
Licensed Content Issue	2
Licensed Content Pages	15
Start Page	282
End Page	296
Type of Use	reuse in a journal/magazine
Requestor type	academic/educational institute
Intended publisher of new work	Other
Portion	figures/tables/illustrations
Number of figures/tables/illustrations	2
Format	electronic
Are you the author of this Elsevier article?	No
Will you be translating?	No
Original figure numbers	Table 2, Table S6
Title of the article	Targeted agents for second-line treatment of advanced hepatocellular carcinoma
Publication new article is in	World Journal of Gastrointestinal Oncology
Publisher of the new article	wjgnet
Author of new article	Lorenza Rimassa

Expected publication date Sep 2019
Estimated size of new article 1
(number of pages)
Requestor Location Lorenza Rimassa
 Via Savona 3A

 Milan, Milan 20144
 Italy
 Attn: Lorenza Rimassa
Publisher Tax ID GB 494 6272 12
Billing Type Credit Card
Credit card info American Express ending in 3003
Credit card expiration 07/2023
Price 124.31 EUR
Tax/VAT (20%) 24.86 EUR
Total 149.17 EUR
Terms and Conditions

INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.
3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."
4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at permissions@elsevier.com). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.
6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this